{"doi":"10.1111/vop.70125","title":"Topical Omidenepag Isopropyl Lowers Intraocular Pressure in Normal and Glaucomatous Cats: A Pilot Study","abstract":"PURPOSE: To evaluate the effects of topical prostaglandin E2 receptor 2 (EP2) agonist, omidenepag isopropyl (OMDI), on intraocular pressure (IOP) and pupil diameter (PD) in normal cats and cats with feline congenital glaucoma (FCG). ANIMALS STUDIED: Ten FCG cats and 8 normal cats. METHODS: In this prospective, randomized, placebo-controlled, masked pilot study, normal and FCG cats received one drop of 0.002% OMDI ophthalmic solution in one eye and artificial tears in the contralateral eye. IOP and PD were measured by a masked observer at baseline and at multiple time points up to 32-36 h post-administration. RESULTS: Topical 0.002% OMDI significantly lowered IOP compared to controls in both normal and FCG cats. In normal cats, the effect was significant up to 12 h after instillation, with a maximal reduction from baseline of 7.3 mmHg (43.5%). In FCG cats, the effect was significant from 2 to 8 h after instillation, with a maximal reduction from baseline of 16.7 mmHg (60.2%). No significant effect on pupil diameter or signs of ocular irritation was observed in either group. CONCLUSIONS: A single topical drop of 0.002% OMDI significantly lowers IOP in normal and FCG cats without inducing miosis. Our findings support that topical selective EP2 agonists may be a promising therapeutic option for feline glaucoma and provide information relevant to dosing intervals for future studies.","journal":"Veterinary Ophthalmology","year":2025,"id":583966,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.94,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":463813,"name":"Julie A. Kiland","orcid":"0000-0002-9019-2346","position":1,"is_corresponding":false},{"id":1496895,"name":"Hayden G. Zaluckyj","orcid":null,"position":2,"is_corresponding":false},{"id":724159,"name":"Anjali Rai","orcid":"0000-0002-3144-4064","position":3,"is_corresponding":false},{"id":1303904,"name":"Virginia Mathu","orcid":null,"position":4,"is_corresponding":false},{"id":381053,"name":"Gillian J. McLellan","orcid":"0000-0002-6505-7476","position":5,"is_corresponding":false},{"id":381051,"name":"Kazuya Oikawa","orcid":"0000-0003-2202-4786","position":0,"is_corresponding":true}],"reference_count":11,"raw_metadata":null,"created_at":"2026-07-19T02:59:07.970345Z","pmid":"41332294","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}